Hepatitis B

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Data Elements

DEMOGRAPHICS

Diagnosis
Age
Gender
Race / Ethnicity
BMI
Height / Weight
Genotype
Fibrosis Score

LABS

CBC
ALT / AST
HBV Viral Load
Serum Creatinine
eGFR
HbA1c
HBeAg, HBeAb
APRI score
Bone Density

PRIOR HISTORY

Prior Treatment Status
Prior Treatment Regimen
Duration of Therapy
Reason for Failure
Prior Transplant
Smoking Status
Illicit Drug Use

COMORBIDS

HIV Coinfection
Anxiety
Depression
Hypertension
Diabetes
Chronic Kidney Disease
Hyperlipidemia
Hemodialysis

PROVIDERS

Type (Physician, NP, PA)
Specialty
Academic vs Community
Specialty Pharmacy

PAYERS

Type (Commercial, Medicare, Medicaid, Dual Eligible)
Payer Name
Self-Pay and Patient Assistance
Eligibility
Correct PA form
Denial Reason

PA TIMELINE

PA Submitted Date
Approval / Denial Date
Appeals Submitted

DISPENSING INFO

Current Treatment Regimen Rx
Intended Regimen
Actual Regimen
Duration
Dispensed Regimen
Gaps in Therapy

Publications

2022

First-Line Therapies for Hepatitis B in the United States: A 3-year Prospective and Multicenter Real-World Study after Approval of Tenofovir Alefenamide

Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma-Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie-Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, and K. Rajender Reddy

DOI: 10.1002/hep4.1964

Manuscript Published in: Hepatology Communications

Date of Publication: April 21, 2022

2020

Longer-Term Experience with Tenofovir Alafenamimde (TAF) in HBV-Infected Patients : Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression

K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT457

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020

Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT448

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020

Hepatitis B Treatment Patterns in US Clinical Care Following TAF Approval

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Kimmi Cox, and Nezam Afdhal

DOI: 10.1016/j.jval.2020.04.484

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020

2019

Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. October 2019; 70 (suppl 1): Abstract #486

Poster Presented at: American Association for the Study of Liver Disease (AASLD)

Conference dates: November 8, 2019 - November 12, 2019

Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression

K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. October 2019; 70 (suppl 1): Abstract #487

Poster Presented at: American Association for the Study of Liver Disease (AASLD)

Conference dates: November 8, 2019 - November 12, 2019

Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Janna Radtchenko, and Nezam Afdhal

DOI: 10.1016/j.jval.2019.04.883

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019

Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal

DOI: 10.1016/S0618-8278(19)30912-0

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019

Effectiveness and Safety with Tenefovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal

DOI: 10.1007/s12072-019-09936-5: Abstract#627

Oral Presented at: Asian Pacific Association for the Study of the Liver (APASL)

Conference dates: February 20, 2019 - February 24, 2019

2018

Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network

Ho Bae, Michael Curry, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. October 2018; 68 (suppl 1): Abstract #445

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal

Journal of Hepatology. October 2018; 68 (suppl 1): Abstract #423

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018